Jupiter Neurosciences Secures Exclusive U.S. Rights to PharmAla's ALA-002 in Deal Valued at Up to $100 Million
核心洞察
Jupiter Neurosciences (搜索) (NASDAQ: JUNS) has entered a definitive license agreement with PharmAla Biotech (搜索) for perpetual exclusive U.S. rights to ALA-002, an FDA-designated New Chemical Entity.
The transaction is valued at up to $100 million, including a $3.3 million upfront payment split between cash and JUNS common stock, plus development, regulatory, and commercial milestone payments.
ALA-002 is a patented, non-racemic MDMA formulation engineered for improved cardiovascular safety and reduced abuse liability, targeting treatment-resistant PTSD (搜索) and other neuropsychiatric conditions.
Jupiter Neurosciences (搜索), Inc. (NASDAQ: JUNS) and PharmAla Biotech (搜索) Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) announced on July 21, 2026, that they have entered into a definitive license agreement granting Jupiter perpetual exclusive U.S. rights to ALA-002, a patented, non-racemic MDMA formulation with New Chemical Entity (NCE) designation from the U.S. Food and Drug Administration. The transaction carries a potential value of up to $100 million, inclusive of milestone payments and exclusive of ongoing royalties.
"This partnership with PharmAla is exactly the kind of high-conviction, strategically aligned transaction we have been working toward," said Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences (搜索). "This deal is genuinely transformative: Jupiter now holds two independent clinical-stage programs across two distinct CNS sectors — JOTROL™ targeting neurodegeneration in Parkinson's disease (搜索), and ALA-002 targeting neuropsychiatric disorders — two areas where patients have waited far too long for meaningfully better treatment options."
Transaction Structure and Financial Terms
Under the terms of the agreement, Jupiter will pay an upfront fee of $3.3 million, comprising $1.5 million in cash and $1.8 million in JUNS common stock subject to a 120-day lock-up period. The deal includes a $3.3 million development milestone payment upon enrollment of the first patient in a Phase 3 trial, a $20 million regulatory milestone upon U.S. New Drug Application (NDA) approval, and three commercial milestones of $10 million, $30 million, and $33.3 million triggered at $333 million, $1 billion, and $2 billion in cumulative U.S. net sales, respectively. A 3% royalty on net sales will commence after the third commercialization milestone is achieved.
Will Avery, CFO of PharmAla Biotech (搜索), noted: "Structuring this transaction as an out-license of U.S. rights allows PharmAla to unlock value from ALA-002 without diluting our interest in the asset elsewhere, and without taking on the full cost of U.S. clinical development. The upfront payment, potential milestones and ongoing royalty are intended to support the Company's continued growth."
ALA-002: A Differentiated Psychedelic Therapeutic
ALA-002 is PharmAla's lead drug candidate — a patented, non-racemic MDMA formulation that has received NCE designation from the FDA, which provides enhanced regulatory protection and a five-year data exclusivity period upon approval. The molecule has been designed with the goal of delivering an improved cardiovascular safety profile and reduced abuse liability relative to racemic MDMA, while preserving the pro-social and therapeutic properties associated with MDMA-assisted psychotherapy.
PharmAla's MDMA supply is currently active in U.S. government-sponsored clinical trials conducted by the Department of Veterans Affairs (VA) and the Defense Health Agency (DHA). Under the agreement, PharmAla will continue to manufacture ALA-002 drug product for Jupiter under commercial terms to be negotiated, which the companies state will greatly accelerate Jupiter's development timelines.
Nicholas Kadysh, Founding Chief Executive Officer of PharmAla Biotech (搜索), stated: "PharmAla developed ALA-002 with the goal of delivering a greatly improved MDMA-based therapeutic candidate, with an improved safety profile, for patients who need better treatment options for a range of neuropsychiatric disorders."
Regulatory Tailwinds and Market Opportunity
The transaction arrives at a pivotal moment in U.S. regulatory policy. On April 18, 2026, President Donald J. Trump signed an Executive Order titled "Accelerating Medical Treatments for Serious Mental Illness," directing the FDA and DEA to expand access to investigational psychedelic therapies. Key provisions include a Right to Try pathway for eligible patients, Commissioner's National Priority Vouchers enabling expedited FDA review timelines of one to two months for psychedelic drugs with Breakthrough Therapy designation, and $50 million in federal funding through ARPA-H for state and federal psychedelic medicine programs.
Jupiter's management believes the evolving regulatory environment may allow the company to benefit from accelerated development pathways for eligible psychedelic therapeutics. The U.S. psychedelic therapeutics market was estimated at $3 billion in 2024 and is projected to grow to $8 billion by 2030, according to Strategic Market Research, addressing millions of Americans living with treatment-resistant PTSD (搜索), anxiety, and related neuropsychiatric conditions.
Strategic Transformation for Jupiter
The acquisition expands Jupiter from a single-program company into a dual clinical-stage CNS developer. The company's lead program, JOTROL™ — a proprietary, enhanced-bioavailability resveratrol formulation — is currently in a Phase IIa clinical trial for Parkinson's disease (搜索). Alison Silva, President and Chief Business Officer of Jupiter Neurosciences (搜索), emphasized the strategic significance: "We've spent the past few months aligning strategy and mobilizing for execution in the space of psychedelic medicines, exemplified by the two new experts we have brought onto our Board of Directors, Drs. Tomas Philipson and Andrew Cutler. The next 12 months will be transformative for Jupiter."
Both companies acknowledged that ALA-002 is an investigational product that has not been approved by the FDA or any other regulatory authority, and its safety and efficacy have not been established. The advancement of both clinical-stage programs remains subject to significant clinical, regulatory, and financing risks.